Eisai gets Japanese approval for pediatric drug
Vasolan is a calcium channel blocking agent which suppresses tachyarrhythmia by blocking the influx of calcium ions into cells and slowing cardiac excitation. Currently, Eisai seeks to establish
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
PRS-080 demonstrated Anticalins’ ability to encapsulate small targets like hepcidin with specificity and potency. In the trial, PRS-080 displayed sub-nanomolar potency, which translated into cell-based and in-vivo efficacy.
Inspra (eplerenone) is a steroid nucleus-based mineralcorticoid receptor (MR) antagonist with a higher degree of selectivity than spironolactone. In the Phase 3B, multinational, randomized, double-blind placebo-controlled, parallel-group trial,